We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

The approval covers all 27 European Union member states. Tresiba (insulin degludec) is a once-daily new-generation based insulin analogue with an ultra-long duration of action. Ryzodeg (insulin ...

Novo Nordisk stock gains as it reports better-than-expected fourth-quarter 2024 results driven by strong sales of Diabetes ...

The settlement resolves the Attorney General’s 2018 lawsuit alleging that Novo Nordisk deceptively priced its insulin.

Novo Nordisk's long-acting insulin Tresiba is set to gain new hypoglycaemia prevention claims in Europe, giving it an advantage over Sanofi’s top-selling Lantus. Europe's CHMP committee has just ...

Many drugs, including insulin, essentially became free. But the American Rescue Plan made a major change that hit drug companies with even larger penalties for raising prices. In January 2024 ...

Insulin allows cells to absorb and use glucose. In people with insulin resistance, the cells are unable to use insulin effectively. Insulin resistance occurs when cells in the body do not respond ...

Prices for insulin, the essential drug for treating diabetes, have plummetted to their lowest levels in a decade following a rise in generic options. Insulin prices averaged 19 cents per unit as ...